The purpose of the Viral/Cell/Molecular Core is to provide comprehensive support for virological, molecular and primary cell-based studies, in order enhance the productivity and efficiency of established HIV investigators within the Penn/Wistar/CHOP community, facilitate the entrance of new investigators into the field of AIDS research, and promote scientific collaborations among these investigators. The Core provides: (1) a carefully supervised facility for Biosafety Level 3 facility for the performance of containment experiments by investigators without access to individual containment facilities or who require a level of containment greater than currently available; (2) a central repository of prototype, mutant, and well-characterized primary HIV-1 isolates representing different aspects of pathogenesis; (3) a service for primary HIV-1 isolation, titration and characterization; (4) additional virologic services including growth, titration and QA of viral stocks, and cost-efficient HIV p24 & SIV p27 ELISA assay; (5) high volume primary PBMC of specified genotype (ie, CCR5 delta32 homozygous) by leukapharesis, and; (6) support for the use of quantitative real-time PCR technology including machine use and cost-efficient optimized primer/probe sets and reagents prepared in bulk for Core users. The Core also provides training programs in (a) HIV biosafety practices for lab personnel new to HIV research or refresher programs for current research personnel; (b) training in use of realtime quantitative PCR technology including custom primer development & data analysis software, and; (c) assistance to new investigators with practical aspects of virological techniques. It is our expectation that this Core will continue to enhance productivity and collaborations among existing HIV investigators and facilitate the entrance of non-HIV investigators into the field, while providing a mechanism to enhance laboratory biosafety.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
5P30AI045008-08
Application #
7279157
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
2006-07-01
Budget End
2007-06-30
Support Year
8
Fiscal Year
2006
Total Cost
$194,573
Indirect Cost
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Papasavvas, Emmanouil; Lada, Steven M; Joseph, Jocelin et al. (2018) Analytical ART interruption does not irreversibly change pre-interruption levels of cellular HIV. AIDS :
Haas, David W; Bradford, Yuki; Verma, Anurag et al. (2018) Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events. Pharmacogenet Genomics 28:179-187
Bengsch, Bertram; Ohtani, Takuya; Khan, Omar et al. (2018) Epigenomic-Guided Mass Cytometry Profiling Reveals Disease-Specific Features of Exhausted CD8 T Cells. Immunity 48:1029-1045.e5
Brocca-Cofano, Egidio; Xu, Cuiling; Wetzel, Katherine S et al. (2018) Marginal Effects of Systemic CCR5 Blockade with Maraviroc on Oral Simian Immunodeficiency Virus Transmission to Infant Macaques. J Virol 92:
Costea, Paul I; Hildebrand, Falk; Arumugam, Manimozhiyan et al. (2018) Enterotypes in the landscape of gut microbial community composition. Nat Microbiol 3:8-16
Page, Kathleen R; Grieb, Suzanne Dolwick; Nieves-Lugo, Karen et al. (2018) Enhanced immigration enforcement in the USA and the transnational continuity of HIV care for Latin American immigrants in deportation proceedings. Lancet HIV 5:e597-e604
Merlin, Jessica S; Long, Dustin; Becker, William C et al. (2018) Brief Report: The Association of Chronic Pain and Long-Term Opioid Therapy With HIV Treatment Outcomes. J Acquir Immune Defic Syndr 79:77-82
Opondo, Philip R; Ho-Foster, Ari R; Ayugi, James et al. (2018) HIV Prevalence Among Hospitalized Patients at the Main Psychiatric Referral Hospital in Botswana. AIDS Behav 22:1503-1516
Venuto, Charles S; Lim, Jihoon; Messing, Susan et al. (2018) Inflammation investigated as a source of pharmacokinetic variability of atazanavir in AIDS Clinical Trials Group protocol A5224s. Antivir Ther 23:345-351
Clarke, Erik L; Lauder, Abigail P; Hofstaedter, Casey E et al. (2018) Microbial Lineages in Sarcoidosis. A Metagenomic Analysis Tailored for Low-Microbial Content Samples. Am J Respir Crit Care Med 197:225-234

Showing the most recent 10 out of 775 publications